Key clinical point: Bone-targeted α-emitting radioisotopes (radium-223) significantly improve survival in patients with metastatic castration-resistant prostate cancer (CRPC) but not β-emitting radioisotopes (strontium-89).
Major finding: α-emitting radioisotopes were significantly associated with an overall survival benefit (hazard ratio [HR], 0.70; 95% CI, 0.58-0.83), but β-emitting radioisotopes (strontium-89) were not associated with any overall survival benefit (HR, 0.96; 95% CI, 0.84-1.10).
Study details: Meta-analysis of individual patient data from 6 randomized studies including 2,081 patients with metastatic CRPC.
Disclosures: The study was funded by Bayer and Ligue Nationale Contre le Cancer. Several authors reported receiving grants and personal fees from multiple pharmaceutical companies, including Bayer.
Terrisse S. JAMA Oncol. 2019 Dec 12. doi: 10.1001/jamaoncol.2019.4097.